- SEQENS acquired CELLforCURE at the end of 2023.
- SEQENS is seeking a buyer for the Les Ulis site, targeting a takeover in the coming months.
- Decision follows a marked slowdown in cell and gene therapy funding, project cancellations and relocation of bioproduction to the United States.
- Absent a viable buyer, SEQENS may cease site operations due to high fixed industrial and regulatory costs; employee support and social dialogue are planned.
Site sale process
CELLforCURE, a SEQENS subsidiary specializing in development and contract manufacturing of cell and gene therapies, is seeking a buyer for its Les Ulis site; SEQENS aims to secure a takeover in the coming months.
Drivers
The decision follows SEQENS's acquisition of CELLforCURE at the end of 2023 and reflects a marked slowdown in cell & gene therapy funding, suspensions or cancellations of client projects, and a trend toward relocating bioproduction to the United States.
Financial position and potential outcome
High fixed costs tied to the site's industrial and regulatory requirements, combined with a weakened project pipeline despite efforts to reposition the site as a multi‑client platform, mean continued operation is unsustainable without a credible industrial buyer; absent that, SEQENS may consider complete cessation of site activities.
Employee measures
SEQENS and CELLforCURE state employee support is a priority and say they will engage in social dialogue to define measures for impacted staff if necessary.
